CTNNB1 and breast carcinoma: These data identify a novel CS-based control mechanism for a Wnt/beta-catenin-collagen I pro-tumorigenic axis, and provide evidence for a potential therapeutic use of CS-E as an inhibitor of Wnt/beta-catenin signaling in breast cancer.